If you’re a migraine sufferer, you’ll know how critical it is to find some form of relief from the pain, nausea and dizziness. Simple movements like gazing out the window, checking your phone or playing music become impossible — never mind trying to get through the work day or take care of family.

That’s why a new migraine injection, erenumab (Aimovig), poses promising possibilities for some migraine sufferers.

For some people with debilitating migraines, this medicine may not be available in their country, even though it is approved by regulatory bodies. Potentially for months, or even years. There are ways to import the medicine for personal use, but most people don’t have this knowledge and might not have the logistical understanding of what’s needed. You can get a better understanding of market access delays on our home page. We provide all the knowledge needed and should you wish to order, our team of qualified pharmacists and professionals will guide you through the process.

What is erenumab (Aimovig)?

Erenumab (Aimovig) is a migraine injection, normally taken once per month. It’s unique because it is the first and only CGRP receptor blocker for migraine. It works by aiming to stop the onset of migraines before they arrive, rather than only working to treat the symptoms and pain of migraines after they arrive. Results also show that erenumab may be helpful in reducing the severity of migraines when they do happen.

To take the medicine, it's expected that patients will inject themselves. The injection process is made as simple as possible: the medicine arrives in an applicator package, with a very thin needle.

In this video, an American doctor shows how to self-administer this medicine.



Patients inject themselves once monthly with the 70mg injection, though some patients find it works better to use two 70mg injections at once (therefore taking a dosage of 140mg). The thigh, stomach or upper arm are the best places to take the injection.

How does erenumab (Aimovig) work?

The active ingredient in Aimovig is called erenumab. It’s an antibody that connects with a receptor and prevents the receptor from working.

The effect is that the activity of the molecule that’s thought to play a role in migraine attacks, is reduced. The molecule, in this case, is called calcitonin gene-related peptide (CGPR).

How effective is it?

The good news is, the effectiveness of erenumab does not seem to be affected by age, gender, or race – based on the clinical trial results.

The trials also showed that erenumab works similarly for those who have episodic (less than 15 migraines per month) migraines and those who have chronic migraines (more than 15 migraines per month), which suggests it may be a useful treatment for all kinds of people, who have all kinds of migraines.

In the clinical trials for Aimovig, the most common side effects are a reaction where the medicine is injected, and constipation. Erenumab may reduce the severity and number of migraines experienced in a month, and therefore may have significant benefits for those who’ve struggled with the debilitating condition for years.

Have you used erenumab (Aimovig)? Share your experience.

If you have already used erenumab please let us know, because we would like to share real experiences of using this novel medicine with other migraine sufferers. Email us at: support@thesocialmedwork.com



Are you a migraine sufferer? 

If you suffer from migraines and are interested in sourcing treatment options not available in your country, head to our home page to find out more about how we can help you.